tirzepatide ελλαδα SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Newer Weight-Loss Drugs Not Cost-effective

This combined mechanism effectively reduces cravings, enhances blood sugar management, and aids in digestion

No contraindication is listed in the UK product information for using these medicines concurrently , and co-prescribing can be appropriate when clinically indicated

Annual Review of Nutrition , 34 , 281303

Secondary endpoints were the percentage of patients attaining 5, 10, 15, and 20% weight loss and improvements in metabolic, cardiovascular, and comorbidities after 12 months of follow-up

Pediatr Nephrol 30:945951

Recent randomized double-blind trials showed that treatment with GLP-1R agonists reduces cardiovascular events, stroke, and nephropathy 8,9